You are using an older browser version. Please use a supported version for the best MSN experience.

$2.8M Zolgensma spinal muscular atrophy treatment approved by Health Canada

Health Canada has approved Zolgensma, a $2.8 million life-saving gene therapy for toddlers that replaces the dysfunctional gene which causes spinal muscular atrophy Type 1. As Morgan Black explains on the noon news, it's exciting news for several Alberta families.
image beaconimage beaconimage beacon